ClinicalTrials.gg
Not yet recruitingNCT07949643Updated Nov 19, 2026

Operator-Assisted Oscilla Audiometry as a Basis for Hearing Aid Fitting (The Oscilla Validation Study)

An interventional study of Paired audiometry (Oscilla A60 and manual audiometry) and Oscilla-based hearing aid fitting in Hearing Loss, Sensorineural and Presbyacusis, sponsored by Aalborg University Hospital. Not yet recruiting at 2 sites in Denmark. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by Aalborg University Hospital · Not applicable, Interventional, and Diagnostic

How we know

Updated Nov 19, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
268
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Hearing Loss, Sensorineural with a site in Denmark — 5 open to participants now, 6 under way, none of them phase 3. Hearing Loss, Sensorineural · Denmark.

Started
2026
with 1 other
No phase
5 of 10
2 open now
Registered
10th of 10
by date
Lead sponsor
2 of 10
Aalborg University Hospital

Among the 10 studies in Hearing Loss, Sensorineural with a site in Denmark, this one is one of 2 that started in 2026, is one of 5 with no phase, and was the 10th registered.

Hearing Loss, Sensorineural

348 studies on the registry are indexed under Hearing Loss, Sensorineural; 103 are open to participants now.

Browse Hearing Loss, Sensorineural studies →

Open to participants now

5 of the 10 studies in Hearing Loss, Sensorineural with a site in Denmark are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in Denmark have not opened yet or have stopped. Only those recruiting at a site in Denmark →

Who these studies take

Of the 70 Hearing Loss, Sensorineural studies recruiting now, 39 (56%) set no upper age limit and 19 (27%) stop at 75 or younger; 26 take children under 18; 17 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Hearing Loss, Sensorineural with a site in Denmark, or all of them as a file.
02

Study summary

The purpose of this study is to find out whether hearing tests performed with the Oscilla A60 audiometer, where the patient largely tests themselves with minimal staff assistance, are accurate enough to be used for diagnosing hearing loss and as the sole basis for fitting hearing aids. Adults referred for their first hearing aids at Aalborg University Hospital will have their hearing tested both with the Oscilla audiometer and by a trained audiology assistant at the same visit. Participants are then randomly assigned to receive hearing aids fitted based on either the Oscilla hearing test or the audiology assistant's hearing test. The main questions are: (1) Do the Oscilla results agree with the audiology assistant's results for both air-conduction and bone-conduction hearing thresholds? (2) Do participants fitted based on the Oscilla test report a hearing benefit that is not worse than that of participants fitted based on the standard test, two months after fitting?

Read the detailed description

Demand for audiometric testing in public hearing clinics is increasing due to population ageing. Operator-assisted automated audiometry may expand capacity, but its use as the sole basis for hearing aid prescription, and its accuracy for bone-conduction (BC) thresholds, has not been established. This single-site study at the Department of Audiology, Aalborg University Hospital (locations in Aalborg and Hobro) enrols 268 first-time hearing aid users with uncomplicated, symmetric sensorineural hearing loss.

At Visit 1, all participants undergo both Oscilla A60 audiometry (air conduction [AC] 250-8000 Hz; BC 250-4000 Hz) and standard manual audiometry by an audiology assistant (reference standard), in randomised order. Agreement between methods is assessed with Bland-Altman analysis against pre-specified acceptance criteria (95% CI of bias within ±5 dB; 95% limits of agreement within ±15 dB for AC and ±20 dB for BC). After confirmation of eligibility, participants are randomised 1:1, stratified by hearing loss severity (PTA-4 ≤45 vs >45 dB HL) and location, to hearing aid fitting based on the Oscilla audiogram or the audiology assistant audiogram. All participants are fitted bilaterally with BTE/RIC hearing aids to the NAL-NL2 target, verified with automated real-ear measurements (within ±5 dB). Volume control and app connectivity are disabled until the two-month follow-up. The primary patient-reported outcome is the change in SSQ12 total score from baseline to two months post-fitting, with a non-inferiority margin of -0.81 points. Secondary outcomes are IOI-HA, daily hearing aid use (data logging) and SSQ12 subscales. The study is a clinical investigation under Article 82 of Regulation (EU) 2017/745.

03

Conditions studied

  • Hearing Loss, Sensorineural
  • Presbyacusis

Keywords

  • automated audiometry
  • operator-assisted audiometry
  • bone conduction
  • hearing aid fitting
  • non-inferiority
  • real-ear measurement
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults (≥18 years) referred for first-time hearing aid fitting at the Department of Audiology, Aalborg University Hospital
  • Uncomplicated sensorineural hearing loss as defined by the Danish national clinical guidelines
  • Hearing thresholds exceeding 20 dB HL at two or more frequencies in the range 0.5-4 kHz
  • Pure-tone average (PTA-4; 0.5, 1, 2, 4 kHz) ≥30 dB HL in the better ear
  • Symmetric hearing loss (PTA-4 difference between ears ≤15 dB)
  • Word discrimination score ≥25% (DANTALE I at PTA + 40 dB HL)
  • Danish native speaker
  • No prior hearing aid experience
  • Able to complete questionnaires online or on paper
  • Written

Exclusion criteria

Exclusion Criteria:

  • Air-conduction thresholds exceeding 80 dB HL at two or more frequencies
  • Air-bone gap >15 dB at one or more frequencies below 1 kHz
  • Fluctuating hearing loss (e.g., Ménière's disease) or ongoing ototoxic medication
  • Ear surgery (ear canal, middle ear or inner ear) within the past 12 months
  • Hearing loss classified as complicated according to national clinical guidelines
  • Visual or motor impairment precluding independent use of the Oscilla system
  • Candidates for in-the-ear hearing aids only (all participants are fitted with BTE or RIC hearing aids)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
268 participants (estimated)

Study arms

  • Experimental
    Oscilla-based fitting

    Hearing aids fitted bilaterally to NAL-NL2 targets based on the Oscilla A60 audiogram, verified with automated real-ear measurement. Volume control and app connectivity disabled for two months (linked interventions: Paired audiometry and Oscilla-based hearing aid fitting).

    Diagnostic Test: Paired audiometry (Oscilla A60 and manual audiometry) · Device: Oscilla-based hearing aid fitting

  • Active comparator
    Manual audiometry-based fitting

    Hearing aids fitted bilaterally to NAL-NL2 targets based on the audiogram obtained by a qualified audiology assistant, verified with automated real-ear measurement. Volume control and app connectivity disabled for two months (linked interventions: paired audiometry and manual audiometry-based hearing aid fitting).

    Diagnostic Test: Paired audiometry (Oscilla A60 and manual audiometry) · Device: Manual audiometry-based hearing aid fitting

Interventions

  • Diagnostic testPaired audiometry (Oscilla A60 and manual audiometry)

    At Visit 1, all participants undergo both operator-assisted Oscilla A60 audiometry (AudioConsole v4.6.0; AC and BC thresholds; operator places the BC headband only) in a quiet room (\<50 dB SPL) and manual pure-tone audiometry (AC and BC, ISO 8253-1) by a qualified audiology assistant in a sound-attenuating booth, in randomised order.

  • DeviceOscilla-based hearing aid fitting

    Bilateral BTE/RIC hearing aid fitting to NAL-NL2 targets using the Oscilla A60 audiogram as the sole audiometric basis, verified with auto-REM (within ±5 dB of target). Other names: Oscilla A60 Diagnostic Audiometer.

  • DeviceManual audiometry-based hearing aid fitting

    Bilateral BTE/RIC hearing aid fitting to NAL-NL2 targets using the audiology assistant audiogram, verified with auto-REM (within ±5 dB of target). Standard clinical practice.

06

What researchers measure

Primary outcomes

  1. Agreement between Oscilla A60 and manual audiometry for air-conduction thresholds

    Bland-Altman mean difference (Oscilla minus manual) and 95% limits of agreement in dB, plus mean absolute difference, at 0.5, 1, 2 and 4 kHz separately. Agreement is acceptable if the 95% CI of the bias is within ±5 dB and the 95% limits of agreement are within ±15 dB. Both ears included, clustering handled with a mixed-effects model.

    Time frame: Visit 1 (Week 0)

  2. Agreement between Oscilla A60 and manual audiometry for bone-conduction thresholds

    As above for bone-conduction thresholds at 0.5, 1, 2 and 4 kHz. Agreement is acceptable if the 95% CI of the bias is within ±5 dB and the 95% limits of agreement are within ±20 dB.

    Time frame: Visit 1 (Week 0)

  3. Change in SSQ12 total score

    Speech, Spatial and Qualities of Hearing Scale, 12-item version; total score = mean of 12 items, range 0-10, higher = better. Non-inferiority if the lower bound of the two-sided 95% CI for the between-group difference in change (Oscilla minus control) is above -0.81 points.

    Time frame: Baseline (Week 0) and 2 months after hearing aid fitting

Secondary outcomes

  1. IOI-HA total score

    International Outcome Inventory for Hearing Aids, Danish version; 7 items scored 1-5, total range 7-35, higher = better outcome. Compared between groups

    Time frame: 2 months after hearing aid fitting

  2. Daily hearing aid use

    Mean daily hearing aid usage time in hours/day from the hearing aid data log, compared between groups

    Time frame: From hearing aid fitting to 2 months after fitting

  3. Change in SSQ12 subscale scores

    Change in the speech, spatial and qualities subscale scores (each range 0-10, higher = better)

    Time frame: Baseline (Week 0) and 2 months after hearing aid fitting

07

Study locations

2 sites
  • Department of Audiology, Aalborg University Hospital
    Aalborg, 9000, Denmark
  • Hearing Clinic, Aalborg University Hospital
    Hobro, 9500, Denmark
08

References and documents

Individual participant data

Plan to share: Undecided — Pseudonymised individual participant data may be shared upon reasonable request after publication, subject to approval under the GDPR and Danish data protection law and a data processing agreement.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Oct 2027, 10 months later.

Of 82 non-industry interventional studies with no phase under Hearing Loss, Sensorineural, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 83. This study's planned 10 months is below that.

Counting every sponsor, half of 162 studies reached it within 22 months; a quarter within 6 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 15, 2026
First posted
Nov 19, 2026
StartEst.
Dec 1, 2026
Primary completionEst.
Oct 31, 2027
CompletionEst.
Oct 31, 2027
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07949643
Responsible party
Lene Dahl Siggaard (Head of Research and Innovation, Aalborg University Hospital) — Principal investigator
First posted
Nov 19, 2026
Start date
Dec 1, 2026 (estimated)
Primary completion
Oct 31, 2027 (estimated)
Completion
Oct 31, 2027 (estimated)
Last update
Nov 19, 2026

Study contacts

Lene D Siggaard, MD, PhD
Contact
lene.dahl@rn.dk
+45 20633492
Camilla L Sørensen, Cand. med.
Contact
c.lorents@rn.dk
Lene D Siggaard, MD, PhD
principal investigator · Department of Otolaryngology, Head- and Neck Surgery and Audiology, Aalborg University Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion